In cancer settings, alterations in TGF-β signaling both in the malignant cells and the tumor microenvironment (i.e., cancer associated myofibroblasts (CAF), endothelial cells and immune cells) may contribute to the progression of HCC as thoroughly described below. Here, TGFB1 is linked to neoplasm.